A randomized trial for combination nicotine replacement therapy for smoking cessation among people with HIV in a low-resourced setting.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Using a two-armed approach, PWH who smoke were randomized to receive either intensive antismoking behavioral counselling or intensive antismoking behavioral counseling plus c-NRT (nicotine patches augmented by nicotine gum).

Recruitment, provision of trial interventions, and follow-up of participants took place in March 2014 through June 2016.

How the Study Was Run

The researchers set it up as a randomized and open-label study.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

Everyone knew when Therapeutic nicotine (patch, non-peptide) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

The researchers conducted an open-label, individually randomized clinical trial.

Self-reported smoking abstinence was biochemically validated with exhaled breath carbon monoxide (CO) and urine cotinine at 6 months.

What Was Measured

The subject headings attached to it are Smoking Cessation, HIV Infections, South Africa, Tobacco Use Cessation Devices, Counseling, Breath Tests and Carbon Monoxide.

What This Means in Plain Language

The paper is a randomized and open-label study of Therapeutic nicotine (patch, non-peptide).

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (AIDS (London, England)), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.